Allergan price target raised to $118 from $104 at Argus Argus increased its target on Allergan as the firm believes that the company reported solid sales and earnings growth ,and has a strong pipeline. The firm expects the company to generate double digit earnings growth over the next three to five years, driven by several positive catalysts. It maintains a Buy rating on the shares.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.